<?xml version='1.0' encoding='utf-8'?>
<document id="28875060"><sentence text="Assessment of the Drug-Drug Interaction Potential Between Theacrine and Caffeine in Humans."><entity charOffset="58-67" id="DDI-PubMed.28875060.s1.e0" text="Theacrine" /><entity charOffset="72-80" id="DDI-PubMed.28875060.s1.e1" text="Caffeine" /><pair ddi="false" e1="DDI-PubMed.28875060.s1.e0" e2="DDI-PubMed.28875060.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s1.e0" e2="DDI-PubMed.28875060.s1.e1" /></sentence><sentence text="&#10;                        Objective:&#10;                     Theacrine, a methylurate class purine alkaloid, triggers diverse pharmacologic responses, including psychostimulatory activity by modulation of adenosinergic and dopaminergic pathways"><entity charOffset="57-66" id="DDI-PubMed.28875060.s2.e0" text="Theacrine" /><entity charOffset="70-81" id="DDI-PubMed.28875060.s2.e1" text="methylurate" /><pair ddi="false" e1="DDI-PubMed.28875060.s2.e0" e2="DDI-PubMed.28875060.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s2.e0" e2="DDI-PubMed.28875060.s2.e1" /></sentence><sentence text=" In a double-blind, placebo-controlled study, theacrine increased energy, concentration, and mood, while reducing fatigue" /><sentence text=" Because caffeine, a methylxanthine purine alkaloid, is frequently coadministered with theacrine, we sought to determine if a pharmacokinetic and/or pharmacodynamic interaction existed between theacrine and caffeine"><entity charOffset="9-17" id="DDI-PubMed.28875060.s4.e0" text="caffeine" /><entity charOffset="21-51" id="DDI-PubMed.28875060.s4.e1" text="methylxanthine purine alkaloid" /><entity charOffset="87-96" id="DDI-PubMed.28875060.s4.e2" text="theacrine" /><entity charOffset="193-202" id="DDI-PubMed.28875060.s4.e3" text="theacrine" /><entity charOffset="207-215" id="DDI-PubMed.28875060.s4.e4" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e0" e2="DDI-PubMed.28875060.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e0" e2="DDI-PubMed.28875060.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e0" e2="DDI-PubMed.28875060.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e0" e2="DDI-PubMed.28875060.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e0" e2="DDI-PubMed.28875060.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e1" e2="DDI-PubMed.28875060.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e1" e2="DDI-PubMed.28875060.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e1" e2="DDI-PubMed.28875060.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e1" e2="DDI-PubMed.28875060.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e2" e2="DDI-PubMed.28875060.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e2" e2="DDI-PubMed.28875060.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e2" e2="DDI-PubMed.28875060.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e3" e2="DDI-PubMed.28875060.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28875060.s4.e3" e2="DDI-PubMed.28875060.s4.e4" /></sentence><sentence text=" &#10;                        Methods:&#10;                     Eight healthy adults received theacrine, as TeaCrine® (25 or 125 mg), caffeine (150 mg), or a combination of theacrine (125 mg) and caffeine (150 mg) in a randomized, double-blind crossover study"><entity charOffset="86-95" id="DDI-PubMed.28875060.s5.e0" text="theacrine" /><entity charOffset="100-108" id="DDI-PubMed.28875060.s5.e1" text="TeaCrine" /><entity charOffset="126-134" id="DDI-PubMed.28875060.s5.e2" text="caffeine" /><entity charOffset="165-174" id="DDI-PubMed.28875060.s5.e3" text="theacrine" /><entity charOffset="188-196" id="DDI-PubMed.28875060.s5.e4" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e0" e2="DDI-PubMed.28875060.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e0" e2="DDI-PubMed.28875060.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e0" e2="DDI-PubMed.28875060.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e0" e2="DDI-PubMed.28875060.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e0" e2="DDI-PubMed.28875060.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e1" e2="DDI-PubMed.28875060.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e1" e2="DDI-PubMed.28875060.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e1" e2="DDI-PubMed.28875060.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e1" e2="DDI-PubMed.28875060.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e2" e2="DDI-PubMed.28875060.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e2" e2="DDI-PubMed.28875060.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e2" e2="DDI-PubMed.28875060.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e3" e2="DDI-PubMed.28875060.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28875060.s5.e3" e2="DDI-PubMed.28875060.s5.e4" /></sentence><sentence text=" Blood samples were collected over a 24-hour period and analyzed by Liquid chromatrography-mass spectrometry/mass spectrometry (LC-MS/MS) for theacrine, caffeine, and paraxanthine"><entity charOffset="142-151" id="DDI-PubMed.28875060.s6.e0" text="theacrine" /><entity charOffset="153-161" id="DDI-PubMed.28875060.s6.e1" text="caffeine" /><entity charOffset="167-179" id="DDI-PubMed.28875060.s6.e2" text="paraxanthine" /><pair ddi="false" e1="DDI-PubMed.28875060.s6.e0" e2="DDI-PubMed.28875060.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s6.e0" e2="DDI-PubMed.28875060.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s6.e0" e2="DDI-PubMed.28875060.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28875060.s6.e1" e2="DDI-PubMed.28875060.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s6.e1" e2="DDI-PubMed.28875060.s6.e2" /></sentence><sentence text=" Pharmacodynamic response markers, heart rate and blood pressure, were recorded" /><sentence text=" &#10;                        Results:&#10;                     Theacrine pharmacokinetics was similar following administration of theacrine alone"><entity charOffset="56-65" id="DDI-PubMed.28875060.s8.e0" text="Theacrine" /><entity charOffset="123-132" id="DDI-PubMed.28875060.s8.e1" text="theacrine" /><pair ddi="false" e1="DDI-PubMed.28875060.s8.e0" e2="DDI-PubMed.28875060.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s8.e0" e2="DDI-PubMed.28875060.s8.e1" /></sentence><sentence text=" Caffeine coadministration increased maximum plasma concentration and area under the curve of theacrine without altering theacrine half-life"><entity charOffset="1-9" id="DDI-PubMed.28875060.s9.e0" text="Caffeine" /><entity charOffset="94-103" id="DDI-PubMed.28875060.s9.e1" text="theacrine" /><entity charOffset="121-130" id="DDI-PubMed.28875060.s9.e2" text="theacrine" /><pair ddi="false" e1="DDI-PubMed.28875060.s9.e0" e2="DDI-PubMed.28875060.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s9.e0" e2="DDI-PubMed.28875060.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s9.e0" e2="DDI-PubMed.28875060.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28875060.s9.e1" e2="DDI-PubMed.28875060.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s9.e1" e2="DDI-PubMed.28875060.s9.e2" /></sentence><sentence text=" Theacrine had no impact on caffeine or paraxanthine pharmacokinetics"><entity charOffset="1-10" id="DDI-PubMed.28875060.s10.e0" text="Theacrine" /><entity charOffset="28-36" id="DDI-PubMed.28875060.s10.e1" text="caffeine" /><entity charOffset="40-52" id="DDI-PubMed.28875060.s10.e2" text="paraxanthine" /><pair ddi="false" e1="DDI-PubMed.28875060.s10.e0" e2="DDI-PubMed.28875060.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s10.e0" e2="DDI-PubMed.28875060.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s10.e0" e2="DDI-PubMed.28875060.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28875060.s10.e1" e2="DDI-PubMed.28875060.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28875060.s10.e1" e2="DDI-PubMed.28875060.s10.e2" /></sentence><sentence text=" There was no difference between treatment groups with regard to heart rate or systolic/diastolic blood pressure" /><sentence text=" &#10;                        Conclusions:&#10;                     Coadministration of theacrine and caffeine results in a clinically significant pharmacokinetic interaction, viz"><entity charOffset="80-89" id="DDI-PubMed.28875060.s12.e0" text="theacrine" /><entity charOffset="94-102" id="DDI-PubMed.28875060.s12.e1" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.28875060.s12.e0" e2="DDI-PubMed.28875060.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s12.e0" e2="DDI-PubMed.28875060.s12.e1" /></sentence><sentence text=", increased theacrine exposure"><entity charOffset="12-21" id="DDI-PubMed.28875060.s13.e0" text="theacrine" /></sentence><sentence text=" Enhanced oral bioavailability is the most likely mechanism by which caffeine alters theacrine exposure"><entity charOffset="69-77" id="DDI-PubMed.28875060.s14.e0" text="caffeine" /><entity charOffset="85-94" id="DDI-PubMed.28875060.s14.e1" text="theacrine" /><pair ddi="false" e1="DDI-PubMed.28875060.s14.e0" e2="DDI-PubMed.28875060.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s14.e0" e2="DDI-PubMed.28875060.s14.e1" /></sentence><sentence text=" However, further studies examining the contribution of presystemic elimination mechanisms, for example, efflux transport and/or gut metabolism, to theacrine bioavailability are needed to confirm the exact mechanism(s)" /><sentence text=" Hemodynamic parameters were unaltered despite the pharmacokinetic interaction, suggesting that coadministration of caffeine and theacrine is safe at the doses administered"><entity charOffset="116-124" id="DDI-PubMed.28875060.s16.e0" text="caffeine" /><entity charOffset="129-138" id="DDI-PubMed.28875060.s16.e1" text="theacrine" /><pair ddi="false" e1="DDI-PubMed.28875060.s16.e0" e2="DDI-PubMed.28875060.s16.e0" /><pair ddi="false" e1="DDI-PubMed.28875060.s16.e0" e2="DDI-PubMed.28875060.s16.e1" /></sentence><sentence text="" /></document>